Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 5, 2010, Pages 335-340

  Li, Ling ^a,b   Hu, Man ^c   Zhu, Hui ^d   Zhao, Wei ^c   Yang, Guoren ^c   Yu, Jinming ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

FDG; FETNIM; FMISO; Glucose metabolism; Tumor hypoxia

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; GEMCITABINE; NAVELBINE; NITROIMIDAZOLE DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUOROERYTHRONITROIMIDAZOLE; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROGNOSIS; AGED; CELL HYPOXIA; COMPARATIVE STUDY; FEMALE; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 77957066285     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.042     Document Type: Article

References (36)

1. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small-cell lung cancer. J Nucl Med 2009; 50:31S-42S.
2. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with (F-18) fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22:199-212.
3. Grönroos T, Bentzen L, Marjamäki P, et al. Comparison of the biodistribution of two hypoxia markers F-18 FETNIM and F-18 FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004; 31:513-520
4. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
5. Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumour microenvironment. Int J Radiat Oncol Biol Phys 2005; 62:545-553
6. Sørensen M, Horsman MR, Cumming P, et al. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumours. Int J Radiat Oncol Biol Phys 2005; 62:854-861
7. Burgman P, Odonoghue JA, Humm JL, et al. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001; 42:170-175
8. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194:795-800.
9. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets of anticancer therapeutics. Chemotherapy 2007; 53:233-256
10. Kim JW, Gao P, Dang CV. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 2007; 26:291-298
11. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999; 2:159-171
12. Lehtiö K, Oikonen V, Grönroos T, et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med 2001; 42:1643-1652
13. Chung JK, Chang YS, Lee YJ, et al. The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model. Ann Nucl Med 1999; 13:303-308
14. Grönroos T, Eskola O, Lehtiö K, et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001; 42:1397-1404
15. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10:2245-2252
16. Bentzen L, Keiding S, Nordsmark M, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003; 67:339-344
17. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23:1378-1383
18. Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small-cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006; 47:1921-1926
19. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30:844-850
20. Gagel B, Reinartz P, Demirel C, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006; 6:51.
21. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003; 30:695-704.
22. Li L, Yu J, Xing L, et al. Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in non-small-cell lung cancer. Am J Clin Oncol 2006; 29:628-633
23. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small-cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46:253-260
24. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55:1233-1238
25. Lehtiö K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59:971-982
26. Rajendran JG, Schwartz DL, OSullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12:5435-5441
27. Thorwarth D, Eschmann SM, Holzner F, et al. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006; 80:151-156
28. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23:1136-1143
29. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2- deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201-3206
30. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22:3255-3260
31. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small-cell lung cancer. Nucl Med Commun 2002; 23:865-870
32. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small-cell lung carcinoma. Cancer 1998; 83:918-924
33. Dhital K, Saunders CA, Seed PT, et al. [18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000; 18:425-428
34. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small-cell lung cancer. Eur J Cancer 2005; 41:1533-1541
35. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008; 26:1459-1464
36. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 2007; 13:3255-3263